ZACKS INVESTMENT MANAGEMENT - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 269 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.

Quarter-by-quarter ownership
ZACKS INVESTMENT MANAGEMENT ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2021$1,489,000
+5.2%
37,027
+6.4%
0.02%
-4.5%
Q3 2021$1,416,000
-1.0%
34,805
+10.5%
0.02%
-4.3%
Q2 2021$1,431,000
+9.5%
31,503
+0.5%
0.02%0.0%
Q1 2021$1,307,000
-0.7%
31,349
+1.7%
0.02%
-4.2%
Q4 2020$1,316,000
+87.5%
30,821
+15.4%
0.02%
+71.4%
Q3 2020$702,000
-2.9%
26,707
-1.0%
0.01%
-12.5%
Q2 2020$723,00026,9740.02%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders